Subcutaneous · GLP-1 agonist
MET097 / PF-08653944
12 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
12
Active
9
Recruiting
5
Completed
3
Sites
243
Countries
11
Endpoints
203
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
3
Phase 1/2
2
Phase 2
4
Phase 3
3
Trials by status
Not yet recruiting
2
Recruiting
5
Active, not recruiting
2
Completed
3
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
75
Safety / tolerability / PK
52
Cardiometabolic biomarkers
30
Glycemic / diabetes
21
Other (unclassified)
13
Patient-reported / QoL
12
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
12 of 12